不同剂量依倍治疗儿童恶性肿瘤贫血疗效观察.docVIP

不同剂量依倍治疗儿童恶性肿瘤贫血疗效观察 　【摘要】 目的 对两种不同剂量的依倍治疗儿童恶性肿瘤贫血的疗效进行观察。方法 将符合条件的44例恶性肿瘤贫血患儿随机分为2个研究组，分别为依倍50 u/kg体重组和依倍100 u/kg体重组，共治疗8周，每2周进行1次依倍的疗效观察。结果 （1）患儿的Hb值和Hct值在应用依倍后明显升高，4～6周后与治疗前相比差异有显著性（P＜0.05或P＜0.01）。其中依倍50 u/kg体重组在治疗6周后显效，依倍100 u/kg体重组4周显效。（2）依倍50 u/kg体重组的有效率低于依倍100 u/kg体重组（P＜0.05）。其治疗后4周和8周的有效率分别为9.1%（P＞0.05）和27.3%（P＜0.05）；依倍组100 u/kg体重组治疗后4周和8周的有效率分别为28.6%（P＜0.05）和57.1%（P＜0.01）。（3）两组的不良反应发生率和输血需求率差异无显著性（P＞0.05）。结论 依倍50 u/kg体重组治疗儿童恶性肿瘤贫血的疗效低于依倍100 u/kg体重组，两组不良反应无明显差异。 【关键词】 重组人红细胞生成素 恶性肿瘤 贫血 The study of clinical effect of recombinant human erythropoietin with different doses on children’s anemia with maligancies ［Abstract］ Objective To study the clinical effect of recombinant human erythropoietin with different doses on childrens anemia with malignancies.Methods 44 children with maligancies were randomly allocated to two rhEPO groups with 50 u/kg and 100 u/kg respectively.The efficacy of all cases were recorded every two weeks during treatment of eight weeks.Results After treatment with rhEPO,the mean Hb and hematocrit levels of all cases increased gradually,and had statistical significance with those at baseline after four to six weeks of therapy.The significant difference in mean Hb and hematocrit level from baseline was initially found at six weeks after therapy in the 50 u/kg group,and at four weeks after therapy in 100 u/kg group.The adverse events and transfusion rates in the two groups all showed no statistical significance.The efficacy of 50 u/kg group was less than 100 u/kg rhEPO group,with effective rate of 9.1%（P＞0.05）and 27.3%（P＜0.05）after four and eight weeks respectively.The effective rate of 100 u/kg groups was 28.6%（P＜0.05）and 57.1%（P＜0.01）after four and eight weeks respectively.Conclusion The efficacy of 50 u/kg group is less than 100 u/kg group on children’s anemia with malignancies,and there were no statistical difference between the two groups in adverse effects. ［Key words］ recombinant human erythropoietin;maligancy;anemia 迄今为止，不同剂量重组人红细